Shi Xuekun, Guan Yuhua, Jiang Shaoyan, Li Tiandong, Sun Bing, Cheng Huan
Department of Cardiovasology, the Affiliated Cardiovascular Hospital of Qindao University, Qindao, Shaodong, China.
Department of Neurology, the BaZhou People's Hospital of XinJiang Uygur Autonomous Region, XinJiang Uygur Autonomous Region, China.
Arch Med Sci. 2019 Jan;15(1):152-164. doi: 10.5114/aoms.2018.74026. Epub 2018 Mar 8.
The renin-angiotensin system is associated with blood pressure regulation, inflammation, oxidative stress and insulin resistance. It can decrease intracellular oxidative stress. Stimulation with HO leads to increased oxidative stress and activation of the AKT/mTOR pathway. However, the role of renin-angiotensin system inhibitors in oxidative stress-induced endothelial cell dysfunction and HO-induced AKT activation remains unclear.
Human coronary artery endothelial cells (HCAECs) were used. The cells were treated with HO, captopril, the AKT inhibitor MK-2206, and the AKT activator SC79, either separately, or in combination. p53 and ICAM-1 expression, and p-eNOS, p-Akt and mTOR activation were measured by Western blot. Cell viability was assessed by MTT assay. Levels of reactive oxygen species (ROS) were assayed by flow cytometry. Proliferation was monitored by BrdU labeling, while cell migration and invasion were determined by wound healing and Transwell assays, respectively.
The renin-angiotensin system inhibitor captopril reversed HO-induced oxidative stress and apoptosis in HCAECs. Co-treatment with captopril and the AKT inhibitor MK-2206 reduced the HO-induced P53 and ICAM-1 protein expression ( < 0.05). The proliferation, migration and invasion of HCAECs were significantly enhanced by co-treatment with captopril and MK-2206 ( < 0.05).
The study revealed the protective effect of captopril against HO-induced endothelial cell dysfunction through the AKT/mTOR pathway, and its enhancement of cell survival. These findings provide new insights into the protective effects of captopril and novel therapeutic approaches to treatment of cardiovascular disease.
肾素 - 血管紧张素系统与血压调节、炎症、氧化应激和胰岛素抵抗相关。它可降低细胞内氧化应激。HO刺激会导致氧化应激增加以及AKT/mTOR通路激活。然而,肾素 - 血管紧张素系统抑制剂在氧化应激诱导的内皮细胞功能障碍和HO诱导的AKT激活中的作用仍不清楚。
使用人冠状动脉内皮细胞(HCAECs)。细胞分别或联合用HO、卡托普利、AKT抑制剂MK - 2206和AKT激活剂SC79处理。通过蛋白质印迹法检测p53和ICAM - 1表达以及p - eNOS、p - Akt和mTOR激活情况。通过MTT法评估细胞活力。通过流式细胞术检测活性氧(ROS)水平。通过BrdU标记监测增殖,而细胞迁移和侵袭分别通过伤口愈合试验和Transwell试验测定。
肾素 - 血管紧张素系统抑制剂卡托普利可逆转HO诱导的HCAECs氧化应激和凋亡。卡托普利与AKT抑制剂MK - 2206联合处理可降低HO诱导的P53和ICAM - 1蛋白表达(<0.05)。卡托普利与MK - 2206联合处理可显著增强HCAECs的增殖、迁移和侵袭能力(<0.05)。
该研究揭示了卡托普利通过AKT/mTOR通路对HO诱导的内皮细胞功能障碍具有保护作用,并增强了细胞存活能力。这些发现为卡托普利的保护作用及心血管疾病治疗的新方法提供了新见解。